Intellia Therapeutics Inc. (NTLA)

$20.76

+0.74

(+3.7%)▲

Market is closed - opens 7 PM, 29 Apr 2024

Insights on Intellia Therapeutics Inc.

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 13.59M → -1.91M (in $), with an average decrease of 63.9% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -122.22M → -132.16M (in $), with an average decrease of 8.1% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 52.5% return, outperforming this stock by 97.2%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 239.5% return, outperforming this stock by 315.9%

Performance

  • $19.42
    $20.97
    $20.76
    downward going graph

    6.48%

    Downside

    Day's Volatility :7.42%

    Upside

    1.0%

    downward going graph
  • $19.64
    $47.48
    $20.76
    downward going graph

    5.39%

    Downside

    52 Weeks Volatility :58.64%

    Upside

    56.28%

    downward going graph

Returns

PeriodIntellia Therapeutics Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-18.88%
0.5%
0.0%
6 Months
-19.92%
11.7%
0.0%
1 Year
-44.74%
6.2%
2.2%
3 Years
-76.39%
13.5%
-23.0%

Highlights

Market Capitalization
1.9B
Book Value
$11.29
Earnings Per Share (EPS)
-5.42
PEG Ratio
-0.1
Wall Street Target Price
70.96
Profit Margin
0.0%
Operating Margin TTM
7297.44%
Return On Assets TTM
-22.83%
Return On Equity TTM
-42.1%
Revenue TTM
36.3M
Revenue Per Share TTM
0.41
Quarterly Revenue Growth YOY
-9.6%
Gross Profit TTM
-367.9M
EBITDA
-506.3M
Diluted Eps TTM
-5.42
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-5.61
EPS Estimate Next Year
-5.49
EPS Estimate Current Quarter
-1.45
EPS Estimate Next Quarter
-1.43

Analyst Recommendation

Buy
    84%Buy
    15%Hold
    0
    0%Sell
Based on 33 Wall street analysts offering stock ratings for Intellia Therapeutics Inc.(by analysts ranked 0 to 5 stars)
Based on 33 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
28
28
29
Hold
5
5
5
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 241.81%

Current $20.76
Target $70.96

Company Financials

FY18Y/Y Change
Revenue
30.4M
↑ 16.53%
Net Income
-85.3M
↑ 26.35%
Net Profit Margin
-280.42%
↓ 21.8%
FY19Y/Y Change
Revenue
43.1M
↑ 41.63%
Net Income
-92.7M
↑ 8.62%
Net Profit Margin
-215.06%
↑ 65.36%
FY20Y/Y Change
Revenue
58.0M
↑ 34.55%
Net Income
-125.6M
↑ 35.46%
Net Profit Margin
-216.52%
↓ 1.46%
FY21Y/Y Change
Revenue
33.1M
↓ 43.01%
Net Income
-259.7M
↑ 106.83%
Net Profit Margin
-785.76%
↓ 569.24%
FY22Y/Y Change
Revenue
52.1M
↑ 57.69%
Net Income
-490.2M
↑ 88.75%
Net Profit Margin
-940.52%
↓ 154.76%
FY23Y/Y Change
Revenue
36.3M
↓ 30.4%
Net Income
-481.2M
↓ 1.84%
Net Profit Margin
-1.3K%
↓ 385.99%
Q3 FY22Q/Q Change
Revenue
13.3M
↓ 5.45%
Net Income
-111.3M
↑ 11.31%
Net Profit Margin
-838.87%
↓ 126.29%
Q4 FY22Q/Q Change
Revenue
13.6M
↑ 2.31%
Net Income
-116.7M
↑ 4.89%
Net Profit Margin
-859.99%
↓ 21.12%
Q1 FY23Q/Q Change
Revenue
12.6M
↓ 7.12%
Net Income
-92.3M
↓ 20.89%
Net Profit Margin
-732.54%
↑ 127.45%
Q2 FY23Q/Q Change
Revenue
13.6M
↑ 7.84%
Net Income
-123.7M
↑ 33.94%
Net Profit Margin
-909.82%
↓ 177.28%
Q3 FY23Q/Q Change
Revenue
12.0M
↓ 11.78%
Net Income
-122.2M
↓ 1.18%
Net Profit Margin
-1.0K%
↓ 109.39%
Q4 FY23Q/Q Change
Revenue
-1.9M
↓ 115.99%
Net Income
-132.2M
↑ 8.13%
Net Profit Margin
6.9K%
↑ 7913.37%
FY18Y/Y Change
Total Assets
347.3M
↓ 7.69%
Total Liabilities
69.4M
↓ 8.25%
FY19Y/Y Change
Total Assets
334.3M
↓ 3.75%
Total Liabilities
64.4M
↓ 7.2%
FY20Y/Y Change
Total Assets
676.3M
↑ 102.32%
Total Liabilities
149.3M
↑ 131.76%
FY21Y/Y Change
Total Assets
1.3B
↑ 91.4%
Total Liabilities
254.2M
↑ 70.33%
FY22Y/Y Change
Total Assets
1.5B
↑ 17.43%
Total Liabilities
284.5M
↑ 11.92%
FY23Y/Y Change
Total Assets
1.3B
↓ 14.42%
Total Liabilities
250.8M
↓ 11.85%
Q3 FY22Q/Q Change
Total Assets
1.1B
↓ 2.34%
Total Liabilities
259.5M
↑ 12.89%
Q4 FY22Q/Q Change
Total Assets
1.5B
↑ 40.17%
Total Liabilities
284.5M
↑ 9.64%
Q1 FY23Q/Q Change
Total Assets
1.4B
↓ 6.72%
Total Liabilities
227.0M
↓ 20.2%
Q2 FY23Q/Q Change
Total Assets
1.3B
↓ 6.68%
Total Liabilities
218.4M
↓ 3.83%
Q3 FY23Q/Q Change
Total Assets
1.2B
↓ 6.04%
Total Liabilities
205.9M
↓ 5.69%
Q4 FY23Q/Q Change
Total Assets
1.3B
↑ 4.63%
Total Liabilities
250.8M
↑ 21.79%
FY18Y/Y Change
Operating Cash Flow
-61.3M
↓ 6.16%
Investing Cash Flow
-260.8M
↑ 2484.3%
Financing Cash Flow
40.2M
↓ 71.87%
FY19Y/Y Change
Operating Cash Flow
-103.2M
↑ 68.54%
Investing Cash Flow
25.2M
↓ 109.65%
Financing Cash Flow
76.4M
↑ 90.05%
FY20Y/Y Change
Operating Cash Flow
-49.9M
↓ 51.65%
Investing Cash Flow
-214.5M
↓ 951.95%
Financing Cash Flow
371.8M
↑ 386.41%
FY21Y/Y Change
Operating Cash Flow
-225.0M
↑ 350.85%
Investing Cash Flow
-550.8M
↑ 156.79%
Financing Cash Flow
736.7M
↑ 98.15%
FY22Y/Y Change
Operating Cash Flow
-333.3M
↑ 48.11%
Investing Cash Flow
160.3M
↓ 129.11%
Financing Cash Flow
583.0M
↓ 20.87%
Q3 FY22Q/Q Change
Operating Cash Flow
-78.5M
↓ 7.72%
Investing Cash Flow
47.6M
↓ 50.03%
Financing Cash Flow
24.0M
↑ 306.73%
Q4 FY22Q/Q Change
Operating Cash Flow
-89.9M
↑ 14.44%
Investing Cash Flow
-30.2M
↓ 163.29%
Financing Cash Flow
505.8M
↑ 2009.37%
Q1 FY23Q/Q Change
Operating Cash Flow
-109.3M
↑ 21.65%
Investing Cash Flow
-122.2M
↑ 305.44%
Financing Cash Flow
2.2M
↓ 99.56%
Q2 FY23Q/Q Change
Operating Cash Flow
-90.3M
↓ 17.38%
Investing Cash Flow
-34.5M
↓ 71.75%
Financing Cash Flow
2.5M
↑ 13.28%

Technicals Summary

Sell

Neutral

Buy

Intellia Therapeutics Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Intellia Therapeutics Inc.
Intellia Therapeutics Inc.
-23.76%
-19.92%
-44.74%
-76.39%
17.49%
Moderna, Inc.
Moderna, Inc.
-1.15%
39.75%
-18.77%
-40.22%
304.34%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-7.56%
12.46%
14.48%
77.72%
159.17%
Novo Nordisk A/s
Novo Nordisk A/s
-2.8%
32.13%
52.48%
239.51%
414.16%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.96%
10.08%
23.01%
83.3%
130.08%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Intellia Therapeutics Inc.
Intellia Therapeutics Inc.
NA
NA
-0.1
-5.61
-0.42
-0.23
NA
11.29
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.04
26.04
1.46
45.0
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
47.43
47.43
2.4
3.35
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.81
28.81
0.53
16.75
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Intellia Therapeutics Inc.
Intellia Therapeutics Inc.
Buy
$1.9B
17.49%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$41.7B
304.34%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$99.5B
159.17%
26.04
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$562.8B
414.16%
47.43
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$103.6B
130.08%
28.81
36.68%

Institutional Holdings

  • ARK Investment Management LLC

    11.87%

  • BlackRock Inc

    9.38%

  • Vanguard Group Inc

    8.69%

  • State Street Corporation

    4.93%

  • Sumitomo Mitsui Trust Holdings Inc

    3.62%

  • Nikko Asset Management Americas Inc

    3.62%

Corporate Announcements

  • Intellia Therapeutics Inc. Earnings

    Intellia Therapeutics Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

intellia therapeutic’s core mission is to develop curative medicines, utilizing the promise of the crispr/cas9 gene editing technology. the development of crispr/cas9 gene editing technology opens a new frontier in biomedical research and clinical intervention. adapted from a natural cellular process, crispr/cas9 permits the editing of any gene in any organism with unprecedented simplicity and flexibility. the incredible potential of this technology for treating human genetic disease inspired a group of life science veterans to create intellia therapeutics. intellia was founded in 2014 by caribou biosciences and atlas venture, along with a consortium of scientists who have helped define the space. intellia therapeutics holds exclusive access to a broad intellectual property portfolio covering the application of crispr/cas9 technology for human therapeutic use. intellia has built an experienced team of individuals to meet the challenges of bringing crispr/cas9 therapeutics to the

Organization
Intellia Therapeutics Inc.
Employees
526
CEO
Dr. John M. Leonard M.D.
Industry
Health Technology

Discover More

FAQs